ZYUS Life Sciences Corporation announced receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (?FIH?) Clinical Trial for its lead drug product candidate, Trichomylin® softgels.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 CAD | +2.97% |
|
+0.97% | +15.56% |
![Consensus](/images/consensus_flch.gif)
1st Jan change | Capi. | |
---|---|---|
+15.56% | 53.93M | |
+24.62% | 46.56B | |
+45.38% | 41.67B | |
-0.08% | 41.16B | |
+33.26% | 32.4B | |
+20.49% | 28.18B | |
-6.35% | 28.1B | |
+49.06% | 14.52B | |
+47.20% | 13.74B | |
+1.97% | 12.17B |
- Stock Market
- Equities
- ZYUS Stock
- News ZYUS Life Sciences Corporation
- ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels